ID: ALA2414176

Max Phase: Preclinical

Molecular Formula: C28H31ClN2O2

Molecular Weight: 463.02

Molecule Type: Small molecule

Representations

Canonical SMILES:  CN(CCC=C(c1ccccc1)c1ccccc1)C(CCO)C(=O)NCc1ccccc1Cl

Standard InChI:  InChI=1S/C28H31ClN2O2/c1-31(27(18-20-32)28(33)30-21-24-15-8-9-17-26(24)29)19-10-16-25(22-11-4-2-5-12-22)23-13-6-3-7-14-23/h2-9,11-17,27,32H,10,18-21H2,1H3,(H,30,33)

Standard InChI Key:  MOVIWRDBUGATOV-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 463.02

Molecular Weight (Monoisotopic): 462.2074

AlogP: 5.16

#Rotatable Bonds: 11

Polar Surface Area: 52.57

Molecular Species: NEUTRAL

HBA: 3

HBD: 2

#RO5 Violations: 1

HBA (Lipinski): 4

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 1

CX Acidic pKa:

CX Basic pKa: 8.03

CX LogP: 5.05

CX LogD: 4.33

Aromatic Rings: 3

Heavy Atoms: 33

QED Weighted: 0.41

Np Likeness Score: -0.48

References

1. Kowalczyk P, Sałat K, Höfner GC, Guzior N, Filipek B, Wanner KT, Kulig K..  (2013)  2-Substituted 4-hydroxybutanamides as potential inhibitors of γ-aminobutyric acid transporters mGAT1-mGAT4: synthesis and biological evaluation.,  21  (17): [PMID:23859778] [10.1016/j.bmc.2013.06.038]

2. Zaręba P, Sałat K, Höfner GC, Łątka K, Bajda M, Latacz G, Kotniewicz K, Rapacz A, Podkowa A, Maj M, Jóźwiak K, Filipek B, Wanner KT, Malawska B, Kulig K..  (2021)  Development of tricyclic N-benzyl-4-hydroxybutanamide derivatives as inhibitors of GABA transporters mGAT1-4 with anticonvulsant, antinociceptive, and antidepressant activity.,  221  [PMID:34015586] [10.1016/j.ejmech.2021.113512]

Source

Source(1):

• Scientific Literature